Sanofi-Aventis Deutschland GmbH, R&D, Integrated Drug Discovery, Industriepark Hoechst, 65926 Frankfurt am Main, Germany.
Helmholtz Zentrum München, Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), Institut für Medizinalchemie, 30167 Hannover, Germany.
J Org Chem. 2023 May 5;88(9):5597-5608. doi: 10.1021/acs.joc.3c00094. Epub 2023 Apr 6.
The GE81112 series, consisting of three naturally occurring tetrapeptides and synthetic derivatives, is evaluated as a potential lead structure for the development of a new antibacterial drug. Although the first total synthesis of GE81112A reported by our group provided sufficient amounts of material for an initial in depth biological profiling of the compound, improvements of the routes toward the key building blocks were needed for further upscaling and structure-activity relationship studies. The major challenges identified were poor stereoselectivity in the synthesis of the -terminal β-hydroxy histidine intermediate and a concise access to all four isomers of the 3-hydroxy pipecolic acid. Herein, we report a second-generation synthesis of GE81112A, which is also applicable to access further representatives of this series. Based on Lajoie's -ester-protected serine aldehydes as key building blocks, the described route provides both a satisfactory improvement in stereoselectivity of the β-hydroxy histidine intermediate synthesis and a stereoselective approach toward both orthogonally protected and -3-hydroxy pipecolic acid.
GE81112 系列由三个天然存在的四肽和合成衍生物组成,被评估为开发新型抗菌药物的潜在先导结构。尽管我们小组首次报道的 GE81112A 的全合成提供了足够数量的材料,用于对该化合物进行初始深入的生物学分析,但仍需要改进关键构建块的路线,以进行进一步的放大和结构-活性关系研究。确定的主要挑战是 -末端β-羟基组氨酸中间体合成中的立体选择性差,以及四种异构体的 3-羟基哌啶酸的简洁获取。在此,我们报告了 GE81112A 的第二代合成方法,该方法也适用于进一步获得该系列的代表物。基于 Lajoie 的β-酯保护丝氨酸醛作为关键构建块,所述路线提供了β-羟基组氨酸中间体合成中立体选择性的令人满意的改进,以及对两种正交保护的和-3-羟基哌啶酸的立体选择性方法。